Plain-English translation of NCT05098197 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new immunotherapy treatment called GC101 TIL for people with advanced liver, bile duct, or pancreatic cancers. The treatment works by taking immune cells (called tumor infiltrating lymphocytes) that are already in your tumor, growing many more of them in a laboratory, and then putting them back into your body through an infusion. The goal is to help your own immune system fight the cancer more effectively.
Advanced liver and pancreatic cancers are very difficult to treat, and many patients run out of standard treatment options. This medication is being tested because early research suggests that boosting your body's own immune cells might help control these aggressive cancers when other treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
First, doctors will perform a biopsy or surgery to remove part of your tumor so they can collect immune cells from it. These cells will then be sent to a laboratory where scientists will grow billions of copies over several weeks. While that happens, you'll receive two medications (hydroxychloroquine and cyclophosphamide) to temporarily weaken your immune system so the new cells can work better. Finally, you'll receive an infusion of your grown immune cells back into your bloodstream. You'll need to visit the hospital multiple times for testing, monitoring, and follow-up appointments to see how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China